Research study · Frontiers in Pharmacology · 2025
Effects and safety of a CBD-rich Cannabis sativa oil in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial - CANOA - cannabis for osteoarthritis
Verified on PubMed Oxford CEBM Level 1B: Randomized Controlled Trial
A 2025 clinical trial in Frontiers in Pharmacology tested cbd in arthritis. The cannabis oil made no difference in pain relief compared to the inactive oil. This study tests whether a modest daily dose of a cannabidiol-dominant extract can relieve joint pain without causing intoxication.
In plain language
Study overview
Researchers in Brazil studied adult patients with painful knee osteoarthritis to see if a daily plant extract oil rich in cannabidiol helped reduce joint pain and improve daily living. Participants took either the cannabis oil or an inactive oil twice a day for two months while keeping their regular doctor-prescribed medications.
Findings
The cannabis oil made no difference in pain relief compared to the inactive oil. Both groups reported similar improvements in pain, mood, and sleep by the end of the study, and the cannabis treatment caused no serious health concerns or changes in routine blood tests.
Explore Dr. Caplan's interactive tool detailing cytochrome P450 pathways, clinical titration intervals, and physician surveillance rules.
The deeper readScientific analysis
Osteoarthritis is a common inflammatory and degenerative joint disease characterized by associated chronic pain, often ensuing to diminished quality of life. Current pain management options present small benefits and great side effects, driving interest in potential treatments such as cannabis, for its anti-inflammatory and analgesic effects. This trial aimed to assess the efficacy and safety of cannabidiol (CBD) in a full-spectrum cannabis oil in managing osteoarthritis-related pain.
The paper
Citation
Mojoli A, Haider O, Fakih Y, Luz Gonçalves MV, Zepeda Rojas B, Xaia G, et al. Effects and safety of a CBD-rich Cannabis sativa oil in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial – CANOA – cannabis for osteoarthritis. Frontiers in Pharmacology (2025). PubMed 41487518 · DOI
Limitations the authors noted
Delta-9-tetrahydrocannabinol and other minor cannabinoids were below the analytical detection limit (0.075 mg/mL), meaning lack of efficacy may relate to low cannabinoid dosage and undetectable delta-9-tetrahydrocannabinol content. Only one specific cannabidiol-rich formulation and daily dosage (45 mg) was evaluated. Relatively small sample size (45 randomized participants) limits the generalizability of the findings. Short follow-up duration of 60 days.
In practice
Why this matters
This study tests whether a modest daily dose of a cannabidiol-dominant extract can relieve joint pain without causing intoxication. It highlights that a cannabidiol-only approach without significant tetrahydrocannabinol may fail to outperform a placebo for arthritis pain in this specific population. It leaves open whether different ratios, higher strengths, or formulas containing tetrahydrocannabinol might yield better results for joint discomfort.
Frequently asked questions
Clinical Questions & Answers
What were the primary clinical findings regarding Cannabis and Adverse events?
The cannabis oil made no difference in pain relief compared to the inactive oil. Both groups reported similar improvements in pain, mood, and sleep by the end of the study, and the cannabis treatment caused no serious health concerns or changes in routine blood tests.
What study limitations or clinical safeguards should patients keep in mind?
Delta-9-tetrahydrocannabinol and other minor cannabinoids were below the analytical detection limit (0.075 mg/mL), meaning lack of efficacy may relate to low cannabinoid dosage and undetectable delta-9-tetrahydrocannabinol content. Only one specific cannabidiol-rich formulation and daily d...
Browse related research
Condition: Adverse events Condition: Arthritis Condition: Pain Topic: Cannabis Topic: Cannabis extract Topic: CBD
Related on CED Clinic
Back to Daily Research and Patient Questions
Reviewed by Dr. Caplan on October 23, 2026.
This page is general education about a published study. It is not medical advice and does not create a doctor-patient relationship. For care specific to you, book a consultation.